

# **Hepatitis-C Tracking Data Report**

(FY2017 Appropriation Act - Public Act 268 of 2016)

**March 1, 2017**

***Sec. 1878. Not later than March 1 of the current fiscal year, the department shall provide a report to the senate and house appropriations subcommittees on the department budget, the senate and house fiscal agencies, the senate and house policy offices, and the state budget office on hepatitis C tracking data. At a minimum, the report shall include information on the following for individuals treated with Harvoni or any other treatment used to cure hepatitis C during the current fiscal year or a previous fiscal year:***

***(a) The total number of people treated broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.***

***(b) The total cost of treatment.***

***(c) The total cost of treatment broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.***

***(d) The total amount of any rebates that were received from the purchase of hepatitis C specialty pharmaceuticals.***

***(e) Outstanding rebates that the department is expecting to receive.***

***(f) The cure rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.***

***(g) The reinfection rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.***



**Michigan Department of  
Health & Human Services**

RICK SNYDER, GOVERNOR  
NICK LYON, DIRECTOR

## Hepatitis C- Tracking Report

### PA 268 of 2016

*Section 1878. Not later than March 1 of the current fiscal year, the department shall provide a report to the senate and house appropriations subcommittees on the department budget, the senate and house fiscal agencies, the senate and house policy offices, and the state budget office on hepatitis C tracking data. At a minimum, the report shall include information on the following for individuals treated with Harvoni or any other treatment used to cure hepatitis C during the current fiscal year or a previous fiscal year:*

*(a) The total number of people treated broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.*

*(b) The total cost of treatment.*

*(c) The total cost of treatment broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.*

*(d) The total amount of any rebates that were received from the purchase of hepatitis C specialty pharmaceuticals.*

*(e) Outstanding rebates that the department is expecting to receive.*

*(f) The cure rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.*

*(g) The reinfection rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.*

**(a) The total number of people treated broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.**

In Fiscal Year 2015-2016, a total of 563 people were treated through traditional Medicaid and 432 people were treated through the Healthy Michigan Plan, for a grand total of 995 individuals.

**(b) The total cost of treatment.**

In Fiscal Year 2015-2016, a total of \$86,545,268<sup>i</sup> was spent on drugs designed to cure Chronic Hepatitis C. This amount represents the gross pharmaceutical costs prior to any Federal or Supplemental rebates the Medicaid program receives. Rebate information for particular drugs and/or drug classes are confidential under federal law, but rebates generally offset Medicaid pharmacy costs an average of 50%.

**(c) The total cost of treatment broken down by those treated through traditional Medicaid and those treated through the Healthy Michigan plan.**

\$49,182,849 of this total was spent on those treated through traditional Medicaid, while \$37,362,419 was spent on those treated through the Healthy Michigan Plan.

**(d) The total amount of any rebates that were received from the purchase of hepatitis C specialty pharmaceuticals & (e) Outstanding rebates that the department is expecting to receive.**

Due to federal statutes prohibiting disclosure of rebates offered by pharmaceutical manufacturers, we are unable to divulge the total amount of rebates received or outstanding in relation to the specific Hepatitis C drugs. However, we can say that, as the result of aggressive negotiations with drug manufacturers, the average net cost per treatment has been reduced to approximately \$38,000 for the

time period of July 1, 2016 to September 30, 2016. This is an approximate 30% reduction from our original costs for these treatments.

**(f) The cure rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment & (g) The reinfection rate broken down by Metavir Score, genotype, Medicaid match rate, and drug used during treatment.**

To calculate the cure and reinfection rates for those receiving these treatments, practitioners who treated 524 patients with paid claims for these drugs from January 1, 2016 to June 30, 2016 were surveyed. This population was chosen because there would be enough time for all the necessary tests to be given to determine whether the individuals were cured. Of those 524, the practitioners for 364 beneficiaries completed at least part of the survey, but only 222 gave complete responses. We use those 222 in the analysis below. The overall cure rate was 96.3%, and the reinfection rate is 0.0%.

- Cure Rates
  - By Metavir Score<sup>ii</sup>
    - F4: 95.7%
    - F3: 97.8%
    - F2: 96.7%
    - F1: 100.0%
    - F0: 100.0%
  - By Genotype
    - 1a: 99.0%
    - 1b: 94.1%
    - 1 (subtype unknown): 97.9%
    - 2: 87.5%
    - 3: 95.7%
    - 4: 75.0%
  - By Medicaid Match Rate
    - Traditional Medicaid: 96.9%
    - HMP: 95.8%
    - Individuals who changed coverage between Traditional Medicaid and HMP: 100.0%
  - By Drugs Used During Treatment
    - Harvoni: 96.9%
    - Sovaldi: 100.0%
    - Combination of Daklinza and Sovaldi: 92.6%
- Reinfection Rates: 0.0% for all categories

---

<sup>i</sup> The amount presented reflects the cost of drug treatment only. Individuals with Hepatitis C may have received other services/treatment during the reporting period.

<sup>ii</sup> The 37 individuals who had a Metavir score of F0 to F2 and received treatment included those who had other primary insurance coverage that covered the majority of the costs of treatment and those that had a co-morbidity, such as HIV or having received a transplant, which made treatment medically necessary.